We found that the CCL18+ cell density in the tumor samples from chemoresistant patients (n = 103) was dramatically higher than that from responsive patients (n = 156) (Fig. 2A, B), implying that CCL18 participates in breast cancer chemoresistance. This evidence concerns the gene CCL18 and breast carcinoma.